Targeting PI3K Signaling in Cancer: A Cautionary Tale of Two AKTs

Publication date: 11 April 2016
Source:Cancer Cell, Volume 29, Issue 4
Author(s): Jérôme Fortin, Tak W. Mak
AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the unexpected finding that ablation of AKT signaling in hepatocytes leads to hepatocellular carcinoma and enhances the incidence of lung metastases in a toxin-induced liver cancer model.

Teaser

AKT inhibitors represent promising therapeutics for cancers with PI3K-AKT pathway hyperactivation. In this issue of Cancer Cell, Wang et al. (2016) report the unexpected finding that ablation of AKT signaling in hepatocytes leads to hepatocellular carcinoma and enhances the incidence of lung metastases in a toxin-induced liver cancer model.


from Cancer via ola Kala on Inoreader http://ift.tt/1p6EyK7
via IFTTT